Last reviewed · How we verify
Placebo Folic Acid
Placebo Folic Acid is a Small molecule drug developed by National Heart, Lung, and Blood Institute (NHLBI). It is currently FDA-approved for Control arm in cardiovascular clinical trials (e.g., homocysteine reduction studies). Also known as: Vitamin B-9,Folison, Folic placebo, folicap.
Placebo folic acid has no active pharmacological mechanism; it serves as an inert control in clinical trials.
Placebo folic acid has no active pharmacological mechanism; it serves as an inert control in clinical trials. Used for Control arm in cardiovascular clinical trials (e.g., homocysteine reduction studies).
At a glance
| Generic name | Placebo Folic Acid |
|---|---|
| Also known as | Vitamin B-9,Folison, Folic placebo, folicap |
| Sponsor | National Heart, Lung, and Blood Institute (NHLBI) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
As a placebo, this formulation contains folic acid but is used in blinded studies to provide a control arm without active therapeutic effect. Folic acid itself is a B vitamin cofactor essential for nucleotide synthesis and methylation reactions, but when used as a placebo it is intended to have no measurable clinical benefit beyond baseline.
Approved indications
- Control arm in cardiovascular clinical trials (e.g., homocysteine reduction studies)
Common side effects
- No expected adverse events beyond those of folic acid at standard doses
Key clinical trials
- A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer (PHASE3)
- Effect of Vitamin D and Folic Acid on Mild Cognitive Impairment (NA)
- A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer (PHASE3)
- A Study Evaluating Quality of Life Parameters Following Use of Emergen-C (PHASE4)
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) (PHASE3)
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension (PHASE3)
- A Clinical Trial to Investigate the Safety and Efficacy of Papillex® on Abnormal Cervical Cells Caused by HPV. (NA)
- Validation of a Novel Functional Food Designed to Meet the Nutritional Needs of People Living With Parkinson's Disease (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo Folic Acid CI brief — competitive landscape report
- Placebo Folic Acid updates RSS · CI watch RSS
- National Heart, Lung, and Blood Institute (NHLBI) portfolio CI
Frequently asked questions about Placebo Folic Acid
What is Placebo Folic Acid?
How does Placebo Folic Acid work?
What is Placebo Folic Acid used for?
Who makes Placebo Folic Acid?
Is Placebo Folic Acid also known as anything else?
What development phase is Placebo Folic Acid in?
What are the side effects of Placebo Folic Acid?
Related
- Manufacturer: National Heart, Lung, and Blood Institute (NHLBI) — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Control arm in cardiovascular clinical trials (e.g., homocysteine reduction studies)
- Also known as: Vitamin B-9,Folison, Folic placebo, folicap
- Compare: Placebo Folic Acid vs similar drugs
- Pricing: Placebo Folic Acid cost, discount & access